Active	Status	Sponsor type	Region	Phase	Filter
2 Active 8 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
RP-G28 / Qualigen Therap
NCT03563859: Evaluation of Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance	Not yet recruiting	3	525	NA	RP-G28, Placebos	Ritter Pharmaceuticals, Inc.	Lactose Intolerance	05/19	05/19
QN-302 / Qualigen Therap
NCT06086522: Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors	Recruiting	1	54	US	QN-302	Qualigen Theraputics, Inc., Translational Drug Development	Solid Tumor	12/25	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
RP-G28 / Qualigen Therap
NCT03563859: Evaluation of Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance	Not yet recruiting	3	525	NA	RP-G28, Placebos	Ritter Pharmaceuticals, Inc.	Lactose Intolerance	05/19	05/19
QN-302 / Qualigen Therap
NCT06086522: Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors	Recruiting	1	54	US	QN-302	Qualigen Theraputics, Inc., Translational Drug Development	Solid Tumor	12/25	12/26